New Haven, Conn. Bioengineers at Yale and Cornell have created a modified chemotherapy that more effectively reaches and remains at the site of brain tumors by adding a water-soluble polymer to the anti-cancer drug, according to a report in the November-December issue of Bioconjugate Chemistry.
This approach has the potential to increase treatment distances to more than a centimeter, which may be sufficient to prevent the recurrence of human brain tumors, said Mark Saltzman, Goizueta Foundation Professor of Chemical and Biomedical Engineering and senior author on the paper.
Although placing polymer implants directly at the site of tumor is a proven treatment for cancers of the brain, Saltzman says that success of this approach is minimized because in most cases the drug does not penetrate into the brain far enough for optimum treatment and there is rapid clearance of the drug from the site.
To increase the effectiveness of their drug, Saltzmans team attached polyethylene glycol (PEG), an inert water-soluble polymer, to it. They also identified a promising compound that could deliver 11 times more medication to the tumor than the plain drug alone.
According to Saltzman, previous work on direct delivery of chemotherapy agents to the brain has shown that drug penetration is limited by the low diffusion into tissue. To overcome this limitation, clinical investigators have pumped therapeutic agents at high pressure into the brain. However, this works only as long as the pressure-driven flow is applied, and the side effects of this continuous pumping are unknown.
We recently conjugated or bonded PEG to the chemotherapy drug camptothecin and found a substantial increase in the extent of distributi
|Contact: Janet Rettig Emanuel|